Sign In
Buy AZN
$176.43
+1.50 (+0.86%)
At Close: Jun 22, 2026
US bank sees positive risk-reward for AstraZeneca ahead of pivotal heart drug trial
10:43am, Friday, 29'th May 2026
Citi sees the risk-reward balance as favourable for AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) ahead of headline results from a pivotal trial of its heart drug Wainua, expected in the third quarter of 202
CelLBxHealth signs master services agreement with AstraZeneca
02:30am, Friday, 29'th May 2026
CelLBxHealth PLC (AIM:CLBX, FRA:DWV), the circulating tumour cell (CTC) intelligence company, has signed a master services agreement with AstraZeneca PLC (LSE:AZN, NASDAQ:AZN), the FTSE 100 pharmaceu
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca's IMFINZI® (durvalumab) in combination with Bacillus Calmette-Guérin (BCG) induction and maintenance therapy has been approved in the US for the treatm
FDA Extends Review Time for AZN's Camizestrant Combo in Breast Cancer
11:01am, Wednesday, 27'th May 2026
AstraZeneca faces a longer FDA review for camizestrant combo in a certain type of first-line breast cancer after regulators request additional data.
US FDA extends review of AstraZeneca's experimental breast cancer pill
02:23am, Wednesday, 27'th May 2026
AstraZeneca said on Wednesday the U.S. Food and Drug Administration has extended its review deadline for its experimental breast cancer pill camizestrant t
How Big Pharma Is Turning Industrial Heat Into A Strategic Asset
09:41am, Tuesday, 26'th May 2026
Inside a pharmaceutical plant, heat is everywhere—and until recently, almost nobody was paying attention to it.
AZN, Daiichi's Enhertu Gets Positive CHMP Opinion for Solid Tumors
12:40pm, Monday, 25'th May 2026
AstraZeneca and Daiichi's Enhertu wins CHMP backing for HER2-positive metastatic solid tumors. The camizestrant combo also gains a positive CHMP nod.
AZN, Daiichi's Datroway Wins FDA Nod for Expanded Use in Breast Cancer
12:31pm, Monday, 25'th May 2026
AstraZeneca and Daiichi Sankyo get FDA approval for Datroway's expanded use in triple-negative breast cancer treatment.
AstraZeneca: 8% Q1 Revenue Growth And Imfinzi/Ultomiris Trial Data Wins
09:28am, Sunday, 24'th May 2026
I am initiating AstraZeneca at a "Strong Buy," driven by robust Q1 2026 revenue growth and portfolio momentum. The company's Oncology and Rare Disease segments delivered 16% and 15% growth, powered by
TOKYO--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) and AstraZeneca's (LSE/STO/NYSE: AZN) Datroway® (datopotamab deruxtecan-dlnk) has been approved in the U.S. for the treatment of adult patients with
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca advances its ambition to eliminate cancer as a cause of death and transform outcomes for people living with rare diseases with new data across its divers
EU regulator recommends positive opinion of AstraZeneca's experimental breast cancer drug
06:45am, Friday, 22'nd May 2026
A European Medicines Agency committee said on Friday it has adopted a positive opinion of AstraZeneca's experimental breast cancer drug, camizestrant.
3 International ETFs for Investors Looking Beyond U.S. Stocks
09:00pm, Monday, 18'th May 2026
These three international ETFs offer diversification and surprisingly strong dividends -- with the same low expense ratio of 0.07%.
AZN, Daiichi's Enhertu Gets FDA Nod for Two New Breast Cancer Settings
01:31pm, Monday, 18'th May 2026
AstraZeneca and Daiichi win FDA approval for Enhertu in two new HER2-positive early breast cancer treatment settings.
AstraZeneca Gets FDA Nod for New Hypertension Drug Baxfendy
01:01pm, Monday, 18'th May 2026
AZN's Baxfendy wins FDA nod as the first aldosterone synthase inhibitor for adults with uncontrolled hypertension.
